Home-AMA: Healthcare: Industrial Scalability for O&P Production
WithAMA: Healthcare 2026on June 4th putting3D printing in healthcareunder the spotlight, voices from across the industry are weighing in on where the technology is heading.
Among the clearest isEOS, the Munich-founded laser powder bed technology company, which is making the case that the orthotics and prosthetics industry has spent long enough treating additive manufacturing as a prototyping tool, and that the barriers to consistent, scalable, economically viable clinical production are more operational than technical.
Get more health insights, register now for ourAMA: Healthcare 2026 online conference!
Throughput as a Value Proposition: EOS’s Calculated Push into O&P
EOS has been cultivating its position in the orthotics and prosthetics market over several years, expanding application by application across a diverse range of devices: foot insoles, ankle-foot orthotics, back braces, knee braces, prosthetic feet, and pediatric helmets. Each draws on distinct material profiles and machine configurations, reflecting the complexity of a segment where no single setup fits all use cases.
At the core of the company’s production argument is a hardware portfolio built around throughput. Using foot insoles as a benchmark, the output differential across machine tiers becomes concrete: the entry-level FORMIGA P 110 yields roughly 60 parts per 20-hour build, the mid-range EOS P3 NEXT delivers 282 parts in 27 hours, and the large-frame EOS P 770 pushes that to 777 parts across a 53-hour unattended run, a build that requires no operator presence once started. For facilities running multiple machines, the labor equation shifts considerably, and EOS notes that its OPEX costs do not scale linearly with additional systems, a differentiator it positions against competing powder bed technologies.
Near-term commercial focus has landed on the EOS P3 NEXT, where faster cycle times and improved process economics take precedence over a feature-forward redesign. Software and process continuity across the full EOS platform means qualification documentation carries over as facilities scale between machine sizes, reducing the administrative friction that typically slows adoption in regulated clinical environments. “It’s about making the process run faster and focusing on the economics for our customers,” said Dave Krzeminski, Business Development Manager – Polymers.
Materials Expanding the Clinical Range
EOS’s material portfolio has historically centered on Nylon 12 and Nylon 11 for rigid applications, with bio-compatible and additive-free variants available. TPU 1301 has served as the primary elastomer for soft devices. But a newer set of materials is beginning to extend the range of what’s clinically addressable.
Source: 3D Printing Industry
